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Abstract
Introduction: Unexplained hyperammonemic coma in adults can be a medical dilemma in the absence of
triggering factors and known comorbidities. Ornithine transcarbamylase deficiency presents most commonly with
hyperammonemic coma. Although a rare disorder, ornithine transcarbamylase deficiency is the most common of
the urea cycle disorders, which can occur both in children, and less commonly, in adults. The urea cycle disorder is
usually acquired as an X-linked trait, and very rarely, similar to our reported case, may be acquired as a “new”
mutation. Mutations that lead to later-onset presentations may lead to life-threatening disease and may be
unrecognized, particularly when the first clinical symptoms occur in adulthood.
Case presentation: We report the case of a previously healthy 17-year-old white man who developed a prolonged
seizure and a rapid decline in mental status leading to coma over a 3-day period. Analysis of the OTC gene showed
a 119G variant, which was identified in exon 2 of the OTC gene by sequencing.
Conclusions: A diagnosis of ornithine transcarbamylase deficiency should be considered in adult patients who
present with unexplained hyperammonemic coma and for all adult patients presenting with cryptogenic new-onset
seizure and laboratory finding of elevated blood ammonia levels. This reported case highlights the importance of
early recognition of this potentially reversible cause of life-threatening encephalopathy, as timely recognition and
appropriate treatment can be lifesaving.
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Introduction
Ornithine transcarbamylase (OTC) deficiency is a urea
cycle X-linked defect, which is considered the most
prevalent inherited defect of the urea cycle [1]. While
typical presentation occurs in infancy, a few reported
cases of late-onset presentations in adults are well de-
scribed [2]. However, the delayed presentation is most
commonly seen in partial OTC deficiency [2]. Males are
usually more commonly, and most severely, affected
than females [3]. The presentation varies, according to
the degree of X-chromosome inactivation, from mild
symptoms of fatigue and lethargy, to severe encephalop-
athy, and coma leading to death [4].
The urea cycle is the primary metabolic pathway for
the excretion of nitrogenous wastes such as urea. OTC
catalyzes the mitochondrial reaction of ornithine (the
end product of the extraction of urea from arginine)
with carbamoyl phosphate (the first storage form of am-
monia) to produce citrulline. Deficiency of OTC leads to
the formation of excess carbamoyl phosphate; some of
which is excreted as an orotic acid. When this pathway
is overwhelmed, hyperammonemia results. Thus, pa-
tients with OTC deficiency tend to have hyperammone-
mia, elevated levels of orotic acid in the urine, and low
plasma citrulline [5].
Males and heterozygous females with partial OTC de-
ficiency can present from infancy to adulthood. One ob-
servational study of 21 male patients found the age at
presentation ranges from 2 months to 44 years [6]. Fur-
thermore, it was observed that male patients who were
older at presentation had a diverse form of presenting
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symptoms and were associated with higher mortality
rates [6]. This data illustrates the phenotypic variability
of OTC deficiency even in the mild form of the disease
(partial OTC deficiency), where a hyperammonemic cri-
sis can be precipitated easily, progressing very rapidly
into a life-threatening condition. For all individuals with
OTC deficiency, a wide spectrum of neuropsychological
complications have been described, including develop-
mental delay, intellectual disability, attention deficit
hyperactivity disorder (ADHD), and executive function
deficits [7].
Here, we report the case of a previously healthy 17-
year-old man who developed intermittent nausea and
vomiting for 1 week, followed by a witnessed new-onset
prolonged generalized tonic-clonic seizure, and a rapidly
deepening coma over a 3-day period. A week prior to
presentation, he had started to take a high-protein sup-
plement. Investigations for liver disease, drug and alco-
hol use, and infections were all negative. His blood NH3
concentration was remarkably high on initial presenta-
tion, but started to decrease with medical therapy and
dialysis. During recovery, our patient developed
ventilator-associated pneumonia treated with antibiotics,
but unfortunately the course was further complicated by
severe Clostridium difficile colitis and miliaria profunda,
which progressed rapidly resulting in our patient’s death.
The diagnosis of OTC deficiency was confirmed by gen-
etic analysis showing a 119G variant, which was identi-
fied in exon 2 of the OTC gene by sequencing. This case
illustrates the importance of recognizing this very un-
usual presentation of new-onset seizure and with labora-
tory finding of elevated blood ammonia levels related to
underlying partial OTC deficiency. Timely recognition
and appropriate treatment for these cases can be
lifesaving.
Case presentation
A 17-year-old white man, previously healthy, was admit-
ted following a reported new-onset generalized tonic-
clonic seizure. The seizure was witnessed by his mother.
She reported a continuous convulsion lasting for almost
6 minutes associated with urinary incontinence. Prior to
admission, he had generalized body fatigue, intermittent
nausea and vomiting for 1 week, without any associated
features such as fever, chills, diarrhea, abdominal pain,
chest pain, shortness of breath, and weight loss. He was
diagnosed as gastritis in a primary health care clinic, and
was treated symptomatically. Upon further inquiry, he
reported recently joining a local fitness club and starting
on high-protein supplement for 1 week prior to the de-
velopment of the presenting symptoms.
On admission, he was afebrile with normal vital signs.
The neurologic examination revealed that he was inter-
mittently aroused to painful stimuli. His Glasgow Coma
Scale score was 10 (E4, V2, M4), with the remainder of
the examination being nonfocal. Initial laboratory data
showed a normal leukocyte count 10.7 × 109/L (N 4.5–
13 × 109/L), normal glucose, electrolytes and calcium
levels. His liver function tests were as follows: alkaline
phosphatase: 179 IU/L (N 40–129 IU/L), AST = 40 IU/L
(N <40 IU/L), ALT = 166 IU/L (<41 IU/L), total bilirubin
= 8 microm/L (≤17 microm/L), an ammonia level of 787
micromol/L (N 16–60 umol/L) with a normal coagula-
tion panel. His initial chest X-ray, computed tomography
(CT) scan of the brain, and magnetic resonance im-
aging/magnetic resonance angiography (MRI/MRA) of
the brain were all normal. His initial prolonged electro-
encephalography (EEG) showed mild diffuse background
slowing without any evidence of electrographical sei-
zures, or clear epileptiform discharges (Fig. 1).
An ultrasound scan of his abdomen and pelvis with
liver Doppler showed normal hepatic parenchyma and
patent hepatic vessels without any other abnormality.
Over the first 24 hours of admission, he became less re-
sponsive and his ammonia level failed to normalize des-
pite lactulose therapy. He was intubated for airway
protection. A repeat CT of the brain was done on the
second day of critical care admission, showing diffuse ef-
facement of sulcal spaces with decreased attenuation of
the cerebral parenchyma, suggesting mild diffuse cere-
bral edema (Fig. 2). In view of his persistently elevated
serum ammonia levels and brain edema, dialysis was ini-
tiated, and plasma and urine amino acid analysis and
urine organic acid quantitation were performed. The
blood test showed low level of citrulline (7 μM; normal
19–62 μM), while the urine test revealed elevated levels
of orotic acid (27.7 mmol/mol creatinine; normal 0–1.3
mmol/mol creatinine). Based on clinical and laboratory
findings, urea cycle disorder was strongly suspected and
our patient was started on arginine and an ammonia
scavenger therapy, sodium benzoate, with intermittent
hemodialysis. After the third hemodialysis session along
with the medical therapy, our patient’s ammonia levels
had significantly decreased over the course of treatment
(median 55, average 184 μmol/L, range 30–787 μmol/L)
(Fig. 3), but without any observable improvement in his
level of consciousness.
At that time, a repeat EEG showed a very severely at-
tenuated, poorly organized, and nonreactive EEG that
was observed at high sensitivity, indicating a profound
generalized disturbance of cerebral activity (Fig. 4). He
was kept on maintenance medical therapy and intermit-
tent hemodialysis. His ammonia level was subsequently
maintained within normal range without improvement
in the level of consciousness, failing multiple ventilation
weaning trials. During the recovery period, he developed
ventilator-associated pneumonia treated with intravenous
piperacillin/tazobactam for 10 days, but unfortunately, the
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course was further complicated by severe Clostridium dif-
ficile colitis, and miliaria profunda that ended with cardio-
pulmonary arrest and death despite aggressive restitution.
The initial genetic testing for the OTC deficiency did
not show any deletion and no duplication was identified
in the OTC gene by multiplex ligation-dependent probe
amplification (MLPA) analysis. However, and because of
the strong clinical suspicion, this result was not consid-
ered as conclusive, as it could not exclude OTC variants,
where any variants outside of the analyzed region might
not be detectable by MLPA and still might be present.
Sequence analysis of the OTC gene was recommended
and the diagnosis was confirmed showing 119G variant,
which was identified in exon 2 of the OTC gene. Based
on these results, all of our patient’s siblings were recom-
mended to be screened and were referred for genetic
consulting.
Discussion
Adult-onset OTC deficiency is a rare cause of encephal-
opathy. The persistent elevated ammonia level may be
the first clue to the diagnosis. Most of the adult-onset
patients remain asymptomatic, till they present with a
rapid decline in mental status, either spontaneously, or
Fig. 1 This electroencephalography portion of long-term tracing demonstrates background slowing in the range of 6–7 HZ. There is no evidence
of consistent focal or lateralizing findings nor was there any evidence of clear epileptiform discharge. High-pass filter is set at 1 Hz; low-pass filter
at 70Hz; notch filter is off
Fig. 2 Computed tomography brain scan without contrast showing
a generalized loss of the supratentorial grey-white matter differenti-
ation with effacement of sulci indicating increasing degree of diffuse
cerebral edema. Asymmetry of lateral ventricles is seen with slit-like
appearance of anterior horns. An effacement of the basal cisterns
can be noted as well
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Fig. 4 At a sensitivity of 50 μV/CM, a repeated electroencephalogram obtained several days after admission shows diffusely attenuated and
poorly organized background activity. This electroencephalography pattern is suggestive of profound generalized disturbance of cerebral activity.
The calibration mark represents 1 second and 50 μV
Fig. 3 Diagram showing a timeline of the measured ammonia level in the serum, observation of an exceptionally elevated level of 787 umol/L
(normal range = 11–35 umol/L) can be noted on the initial presentation, responding to medical therapy with a gradual decline during the
hospital stay (ammonia scavenger therapy arginine, sodium benzoate and intermittent hemodialysis)
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following a heavy protein challenge, as was the case in
our patient [8]. Our case, similar to the previously few
reported cases of OTC deficiency, presented with a rap-
idly worsening coma that, unfortunately, can be poten-
tially fatal [9]. Indeed, death is an usual outcome of the
disease in its mild forms. However in severe cases, death
may be an evitable outcome, either because of liver fail-
ure or, similar to our patient, due to intercurrent severe
illness and fatal inflammatory response [10]. On the
other hand, seizures have been reported rarely as the
first manifestation of OTC deficiency. Our patient had a
reported prolonged seizure, unlike generalized convul-
sive seizures, which typically last less than 2 minutes.
We realize the limitation of depending on witnesses to
estimate the duration of a convulsive seizure; however,
due to the concern of missing a nonconvulsive seizure
following the reported prolonged seizure, a 6-hour con-
tinuous EEG was obtained, ruling out that possibility.
The basis of treatment of the acute status of hyper-
ammonic coma is to target the plasma ammonia level
to ≤200 μmol through the use of ammonia scavenger
treatment to allow excretion of excess nitrogen, which
is expected to reduce the risk of neurologic damage,
and if needed, a renal replacement therapy can fur-
ther aid to lower the ammonia levels. Our patient’s
ammonia level responded well to treatment, but his
mental status did not. This lack of correlation be-
tween declining ammonia levels and improvement in
mental status is quite puzzling. In fact, a recently re-
ported series of five cases of adult-onset OTC defi-
ciency have demonstrated similar findings, where
three of their patients had a normal ammonia level
days after initiation of treatment but their cognitive
status had not improved, leading to death [11].
Liver transplantation is typically considered in those
who have frequent hyperammonic episodes [12]. After
the acute phase, routine measurement of plasma ammo-
nia, amino acids, and liver function every 3 to 6 months
may be required [7].
The diagnosis of OTC deficiency in adults may be dif-
ficult, as clinical manifestations are nonspecific, and
often episodic in nature, which add more difficulties in
considering the diagnosis. In fact, early diagnosis and
prevention of the metabolic decompensations in adult-
onset cases is crucial to avoid this, unfortunately fatal,
and other negative cognitive outcomes [13]. Moreover,
laboratory findings can be normal outside the acute
phase. In all cases, molecular analysis is the method of
choice to confirm the diagnosis of OTC deficiency. In-
deed, a recently published study analyzed the clinical,
biochemical and genetic parameters of 90 patients from
a single center and revealed various molecular and gen-
etic mutations in patients with OTC deficiency across
different age groups.
Conclusions
Urea cycle disorders are one of the complex medical
metabolic emergencies that occur in infancy until adult-
hood and must be treated promptly to avoid severe brain
injury and death. However, there is a very limited num-
ber of case reports in the literature for cases presenting
in young adults. Our case should call on all physicians
to consider this diagnosis for any adult presenting with
unexplained hyperammonic coma or unexplained
change in mental status. In these cases, every effort
should be made to screen for this condition very rapidly
and to offer immediate treatment along with precise
genetic counseling. Future efforts should look into wid-
ening the knowledge about the combined effect of gen-
etic factors (that is mutations in the OTC gene, variants
in modifier genes or epigenetic features) and environ-
mental conditions to determine the phenotypic expres-
sion of OTC deficiency.
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